Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
The introduction of monoclonal antibodies (mAbs) directed against the calcitonin gene-related peptide (CGRP), or its receptor (CGRPr), revolutionized migraine management due to their high efficacy and few side effects. Data suggest that the CGRP may even be implicated in circadian rhythm, but studie...
Main Authors: | Laura Pilati, Angelo Torrente, Salvatore Di Marco, Salvatore Ferlisi, Giulia Notaro, Marika Romano, Paolo Alonge, Lavinia Vassallo, Ludovica Ferraù, Massimo Autunno, Rosario Grugno, Cecilia Camarda, Filippo Brighina |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/10/3585 |
Similar Items
-
Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
by: Zaira Maraia, et al.
Published: (2021-09-01) -
Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study
by: Gaia Pellitteri, et al.
Published: (2022-05-01) -
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
by: Anna P. Andreou, et al.
Published: (2022-11-01) -
Experience with erenumab: Data from real clinical practice
by: E. Morales Bacas, et al.
Published: (2022-07-01) -
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
by: Taoufik Alsaadi, et al.
Published: (2024-02-01)